The global Lou Gehrigs disease market is expected to grow at a CAGR of 7.2% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of Lou Gehrigs disease and increasing awareness about the disease. The North America region is expected to dominate the global Lou Gehrigs disease market with a share of over 40%. This can be attributed to high prevalence rates in this region and increased awareness about the disease.
Some Of The Growth Factors Of This Market:
- The number of people with ALS is expected to increase by 20% in the next 10 years.
- There are currently no treatments for ALS, so the market is largely dependent on research and development efforts to find a cure or treatment for the disease.
- The average age of diagnosis is 55, but it can be diagnosed at any age from 18-80 years old.
- There are an estimated 30,000 Americans living with ALS today.
- In 2017, there were 2 new drugs approved by the FDA for ALS.
Industry Growth Insights published a new data on “Lou Gehrigs Disease Market”. The research report is titled “Lou Gehrigs Disease Market research by Types (Riluzole, Edaravone (Radicava)), By Applications (Hospital Pharmacies, Retail & Online Pharmacie), By Players/Companies AB Science, Avicena Group, Biogen, BrainStorm Therapeutics, Covis Pharmaceutical Inc., Cytokinetics Inc., Eisai Co. Ltd., GlaxoSmithKline plc., Ionis Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corp., Neuralstem Inc., Neuraltus Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Nutra Pharma Corp., Pharnext SAS, Q-Therapeutics Inc.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lou Gehrigs Disease Market Research Report
By Type
Riluzole, Edaravone (Radicava)
By Application
Hospital Pharmacies, Retail & Online Pharmacie
By Companies
AB Science, Avicena Group, Biogen, BrainStorm Therapeutics, Covis Pharmaceutical Inc., Cytokinetics Inc., Eisai Co. Ltd., GlaxoSmithKline plc., Ionis Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corp., Neuralstem Inc., Neuraltus Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Nutra Pharma Corp., Pharnext SAS, Q-Therapeutics Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Lou Gehrigs Disease Market Report Segments:
The global Lou Gehrigs Disease market is segmented on the basis of:
Types
Riluzole, Edaravone (Radicava)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail & Online Pharmacie
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AB Science
- Avicena Group
- Biogen
- BrainStorm Therapeutics
- Covis Pharmaceutical Inc.
- Cytokinetics Inc.
- Eisai Co. Ltd.
- GlaxoSmithKline plc.
- Ionis Pharmaceuticals, Inc.
- Mitsubishi Tanabe Pharma Corp.
- Neuralstem Inc.
- Neuraltus Pharmaceuticals Inc.
- Newron Pharmaceuticals S.p.A.
- Nutra Pharma Corp.
- Pharnext SAS
- Q-Therapeutics Inc.
Highlights of The Lou Gehrigs Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Riluzole
- Edaravone (Radicava)
- By Application:
- Hospital Pharmacies
- Retail & Online Pharmacie
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lou Gehrigs Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lou Gehrigs disease is a progressive neurodegenerative disorder that affects the central nervous system. It is also known as amyotrophic lateral sclerosis (ALS), or motor neuron disease. Symptoms of Lou Gehrigs disease typically develop gradually and may not be noticeable until late in the illness. The most common symptoms are muscle weakness, difficulty speaking, and difficulty walking. As the condition progresses, patients may experience paralysis and death due to respiratory failure or heart failure.
Some of the major companies in the lou gehrigs disease market are AB Science, Avicena Group, Biogen, BrainStorm Therapeutics, Covis Pharmaceutical Inc., Cytokinetics Inc., Eisai Co. Ltd., GlaxoSmithKline plc., Ionis Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corp., Neuralstem Inc., Neuraltus Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Nutra Pharma Corp., Pharnext SAS, Q-Therapeutics Inc..
The lou gehrigs disease market is expected to register a CAGR of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lou Gehrigs Disease Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Lou Gehrigs Disease Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Lou Gehrigs Disease Market - Supply Chain
4.5. Global Lou Gehrigs Disease Market Forecast
4.5.1. Lou Gehrigs Disease Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Lou Gehrigs Disease Market Size (000 Units) and Y-o-Y Growth
4.5.3. Lou Gehrigs Disease Market Absolute $ Opportunity
5. Global Lou Gehrigs Disease Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Lou Gehrigs Disease Market Size and Volume Forecast by Type
5.3.1. Riluzole
5.3.2. Edaravone (Radicava)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Lou Gehrigs Disease Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Lou Gehrigs Disease Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail & Online Pharmacie
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Lou Gehrigs Disease Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Lou Gehrigs Disease Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Lou Gehrigs Disease Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Lou Gehrigs Disease Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Lou Gehrigs Disease Demand Share Forecast, 2019-2026
9. North America Lou Gehrigs Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Lou Gehrigs Disease Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Lou Gehrigs Disease Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail & Online Pharmacie
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Lou Gehrigs Disease Market Size and Volume Forecast by Type
9.7.1. Riluzole
9.7.2. Edaravone (Radicava)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Lou Gehrigs Disease Demand Share Forecast, 2019-2026
10. Latin America Lou Gehrigs Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Lou Gehrigs Disease Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Lou Gehrigs Disease Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail & Online Pharmacie
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Lou Gehrigs Disease Market Size and Volume Forecast by Type
10.7.1. Riluzole
10.7.2. Edaravone (Radicava)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Lou Gehrigs Disease Demand Share Forecast, 2019-2026
11. Europe Lou Gehrigs Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Lou Gehrigs Disease Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Lou Gehrigs Disease Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail & Online Pharmacie
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Lou Gehrigs Disease Market Size and Volume Forecast by Type
11.7.1. Riluzole
11.7.2. Edaravone (Radicava)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Lou Gehrigs Disease Demand Share, 2019-2026
12. Asia Pacific Lou Gehrigs Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Lou Gehrigs Disease Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Lou Gehrigs Disease Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail & Online Pharmacie
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Lou Gehrigs Disease Market Size and Volume Forecast by Type
12.7.1. Riluzole
12.7.2. Edaravone (Radicava)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Lou Gehrigs Disease Demand Share, 2019-2026
13. Middle East & Africa Lou Gehrigs Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Lou Gehrigs Disease Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Lou Gehrigs Disease Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail & Online Pharmacie
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Lou Gehrigs Disease Market Size and Volume Forecast by Type
13.7.1. Riluzole
13.7.2. Edaravone (Radicava)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Lou Gehrigs Disease Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Lou Gehrigs Disease Market: Market Share Analysis
14.2. Lou Gehrigs Disease Distributors and Customers
14.3. Lou Gehrigs Disease Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AB Science
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Avicena Group
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Biogen
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. BrainStorm Therapeutics
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Covis Pharmaceutical Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Cytokinetics Inc.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Eisai Co. Ltd.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. GlaxoSmithKline plc.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Ionis Pharmaceuticals, Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mitsubishi Tanabe Pharma Corp.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Neuralstem Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Neuraltus Pharmaceuticals Inc.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Newron Pharmaceuticals S.p.A.
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Nutra Pharma Corp.
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Pharnext SAS
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Q-Therapeutics Inc.
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook